TICALIX^®

Generic name: Ticagrelor

Pharmacologic Category: Antiplatelet agent

Dosage Forms: Tablet, Oral (60 mg ,90 mg )

Description:

Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent

Indications:

• Patients with acute coronary syndrome (ACS) or a history of myocardial infarction
• Patients with coronary artery disease (CAD) at high risk for ischemic events
• Patients with acute ischemic stroke (NIHSS ≤5) or high-risk transient ischemic attack (TIA)
• Ticalix® is produced at a GMP approved manufacturing site

Did you know . . . ?

Did you know, every 2.5 minutes, one heart attack occurred again for patients who have survived from prior myocardial infarction?

Ticagrelor remarkably reduces the rate of death from cardiovascular events, myocardial infarction or stroke and recurrent cardiovascular events.